Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,571,040
  • Shares Outstanding, K 18,000
  • Annual Sales, $ 131,310 K
  • Annual Income, $ 52,150 K
  • 60-Month Beta 1.01
  • Price/Sales 11.87
  • Price/Cash Flow 17.32
  • Price/Book 1.90
Trade LGND with:

Options Overview Details

View History
  • Implied Volatility 39.49% ( +4.04%)
  • Historical Volatility 49.85%
  • IV Percentile 52%
  • IV Rank 51.56%
  • IV High 52.07% on 07/12/23
  • IV Low 26.09% on 09/13/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 37
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 1,457
  • Open Int (30-Day) 2,095

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.83
  • Number of Estimates 1
  • High Estimate 0.83
  • Low Estimate 0.83
  • Prior Year 1.10
  • Growth Rate Est. (year over year) -24.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.17 +21.90%
on 04/24/24
88.52 -4.76%
on 05/21/24
+14.42 (+20.63%)
since 04/23/24
3-Month
67.72 +24.50%
on 04/22/24
94.57 -10.85%
on 02/27/24
+8.44 (+11.12%)
since 02/23/24
52-Week
49.24 +71.22%
on 10/27/23
94.57 -10.85%
on 02/27/24
+6.93 (+8.96%)
since 05/23/23

Most Recent Stories

More News
3 Magnificent Growth Stocks to Buy Hand Over Fist

Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.

LGND : 84.35 (-3.36%)
AGEN : 12.18 (+2.27%)
CGC : 8.89 (-5.53%)
CURLF : 4.7900 (-6.45%)
Ligand: Q1 Earnings Snapshot

Ligand: Q1 Earnings Snapshot

LGND : 84.35 (-3.36%)
Ligand: Q4 Earnings Snapshot

Ligand: Q4 Earnings Snapshot

LGND : 84.35 (-3.36%)
Ligand: Q3 Earnings Snapshot

Ligand: Q3 Earnings Snapshot

LGND : 84.35 (-3.36%)
Ligand: Q2 Earnings Snapshot

Ligand: Q2 Earnings Snapshot

LGND : 84.35 (-3.36%)
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y

Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.

BMY : 41.58 (-1.79%)
EXEL : 20.43 (-2.71%)
LGND : 84.35 (-3.36%)
SPRO : 1.4700 (-2.33%)
bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona

bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.

LGND : 84.35 (-3.36%)
PCRX : 30.09 (-2.05%)
BLUE : 0.9456 (-3.86%)
SPRO : 1.4700 (-2.33%)
Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View

Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.

NVAX : 14.98 (-4.59%)
LGND : 84.35 (-3.36%)
ALLO : 2.51 (-5.64%)
ATHA : 2.61 (-0.38%)
Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus

Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.

SNY : 48.83 (-3.04%)
BIIB : 217.75 (-3.31%)
LGND : 84.35 (-3.36%)
DNLI : 18.95 (-5.53%)
Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

LGND : 84.35 (-3.36%)
PCRX : 30.09 (-2.05%)
SPRO : 1.4700 (-2.33%)
VTRS : 10.44 (-2.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 89.30
2nd Resistance Point 88.76
1st Resistance Point 88.02
Last Price 84.35
1st Support Level 86.74
2nd Support Level 86.20
3rd Support Level 85.46

See More

52-Week High 94.57
Last Price 84.35
Fibonacci 61.8% 77.25
Fibonacci 50% 71.90
Fibonacci 38.2% 66.56
52-Week Low 49.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar